Eder Scott Evan
Womens Health (Lond). 2014 Sep;10(5):499-503. doi: 10.2217/whe.14.46.
Ospemifene is a novel, oral selective estrogen receptor modulator that has been approved in the USA for treatment of dyspareunia. The decline in estrogen during menopause creates vulvovaginal changes that can cause symptoms that adversely impact women psychosexually. Many women are reluctant to discuss painful sex and providers must proactively inquire about sexuality issues. Ospemifene has been shown to reverse changes associated with vulvovaginal atrophy and relieve symptoms of dyspareunia. Safety studies of treatment up to 52 weeks have shown ospemifene to be safe with no impact on endometrial hyperplasia/carcinoma, venous thrombotic events or pelvic organ prolapse. Further studies are needed to evaluate its role in bone and breast health.
奥司米芬是一种新型口服选择性雌激素受体调节剂，已在美国获批用于治疗性交困难。绝经期间雌激素水平下降会导致外阴阴道变化，进而引发一些症状，对女性的心理和性生活产生不利影响。许多女性不愿谈论性交疼痛问题，医生必须主动询问性方面的问题。研究表明，奥司米芬可逆转与外阴阴道萎缩相关的变化，并缓解性交困难症状。长达52周的治疗安全性研究表明，奥司米芬安全性良好，对子宫内膜增生/癌、静脉血栓事件或盆腔器官脱垂均无影响。需要进一步研究以评估其在骨骼和乳腺健康方面的作用。
